Baseline characteristics and logistic regression results
| Factor . | Level . | No. of patients . | 12-month MMR rate . | 24-month MMR rate . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentages . | P . | OR (95% CI) . | Percentagesd . | P . | OR (95% CI) . | |||||||
| No MMR . | MMR . | Unifactor analysis . | Multifactor analysis . | No MMR . | MMR . | Unifactor analysis . | Multifactor analysis . | |||||
| Sokal Score at diagnosis | Good | 26 | 40.0 | 60.0 | .063 | .244 | 1.19 (0.19-7.32) | 20.0 | 80.0 | .044 | .788 | 1.94 (0.28-13.30) |
| Intermediate | 30 | 63.3 | 36.7 | 0.40 (0.08-2.10) | 33.3 | 66.7 | 1.46 (0.34-6.19) | |||||
| Poor | 28 | 71.4 | 28.6 | 1 (NA) | 53.6 | 46.4 | 1 (NA) | |||||
| Missing | 19 | |||||||||||
| Hasford Score at diagnosis | Low | 42 | 41.5 | 58.5 | .005 | .278 | 5.08 (0.69-37.6) | 19.5 | 80.5 | .006 | .575 | 2.81 (0.41-19.34) |
| Intermediate | 21 | 66.7 | 33.3 | 2.79 (0.42-18.52) | 42.9 | 57.1 | 1.56 (0.31-7.84) | |||||
| High | 19 | 89.5 | 10.5 | 1 (NA) | 63.2 | 36.8 | 1 (NA) | |||||
| Missing | 21 | |||||||||||
| Age | < 50 | 52 | 54.9 | 45.1 | .842 | .288 | 1.72 (0.63-4.70) | 29.4 | 70.6 | .216 | .074 | 3.02 (0.90-10.16) |
| 50+ | 51 | 56.9 | 43.1 | 1 (NA) | 41.2 | 58.8 | 1 (NA) | |||||
| Sex | Male | 66 | 62.1 | 37.9 | .088 | .374 | 1.58 (0.57-4.35) | 39.4 | 60.6 | .243 | .079 | 3.13 (0.88-11.15) |
| Female | 37 | 44.4 | 55.6 | 1 (NA) | 27.8 | 72.2 | 1 (NA) | |||||
| Spleen size at diagnosis | < 5 | 55 | 42.6 | 57.4 | < .001 | < .001 | 6.48 (2.27-18.47) | 22.2 | 77.8 | .002 | .003 | 5.13 (1.73-15.26) |
| 5+ | 39 | 79.5 | 20.5 | 1 (NA) | 53.9 | 46.1 | 1 (NA) | |||||
| Missing | 9 | |||||||||||
| % Ph+ cells | < 90 | 15 | 28.6 | 71.4 | .029 | .118 | 3.08 (0.75-12.65) | 7.1 | 92.9 | .038 | .241 | 3.83 (0.41-36.16) |
| 90+ | 83 | 61.5 | 38.5 | 1 (NA) | 41.0 | 59.0 | 1 (NA) | |||||
| Missing | 5 | |||||||||||
| Basophils (×10−9/L) (pretreatment) | ≤ 1 | 72 | 46.5 | 53.5 | .005 | .004 | 5.82 (1.74-19.39) | 31.0 | 69.0 | .171 | .473 | 1.53 (0.48-4.87) |
| > 1 | 31 | 77.4 | 22.6 | 1 (NA) | 45.2 | 54.8 | 1 (NA) | |||||
| Eosinophils (×10−9/L) (pretreatment) | < 0.5 | 74 | 56.2 | 43.8 | .927 | .724 | 6.33 (1.72-23.22) | 37.0 | 63.0 | .571 | .816 | 1.15 (0.36-3.72) |
| 0.5+ | 29 | 55.2 | 44.8 | 1 (NA) | 31.0 | 69.0 | 1 (NA) | |||||
| Platelets (×10−9/L) (pretreatment) | < 450 | 68 | 61.2 | 38.8 | .137 | .020 | 0.28 (0.09-0.82) | 38.8 | 61.2 | .306 | .136 | 0.41 (0.12-1.33) |
| 450+ | 35 | 45.7 | 54.3 | 1 (NA) | 28.6 | 71.4 | 1 (NA) | |||||
| White cells (×10−9/L) (pretreatment) | < 20 | 66 | 55.4 | 44.6 | .893 | .565 | 0.72 (0.24-2.19) | 35.4 | 64.6 | .980 | .625 | 1.32 (0.43-4.01) |
| 20+ | 37 | 56.8 | 43.2 | 1 (NA) | 35.1 | 64.9 | 1 (NA) | |||||
| PB blasts (pretreatment) | < 0.2 | 73 | 54.8 | 45.2 | .728 | .366 | 0.49 (0.10-2.29) | 37.0 | 63.0 | .367 | .260 | 0.34 (0.05-2.21) |
| 0.2+ | 16 | 50.0 | 50.0 | 1 (NA) | 25.0 | 75.0 | 1 (NA) | |||||
| Missing | 14 | |||||||||||
| Glivec average daily dose | 600, 600 | 50 | 44.0 | 56.0 | .110 | .130 | 5.40 (1.20-24.37) | 18.0 | 82.0 | .003 | .004 | 10.51 (2.67-41.42) |
| First 6 months, second 6 months | 600, < 600 | 10 | 50.0 | 50.0 | 2.79 (0.39-20.02) | 50.0 | 50.0 | 1.42 (0.26-7.79) | ||||
| < 600, 600 | 20 | 60.0 | 40.0 | 1.89 (0.34-10.41) | 30.0 | 70.0 | 5.59 (1.20-26.03) | |||||
| < 600, < 600 | 18 | 77.8 | 22.2 | 1 (NA) | 66.7 | 33.3 | 1 (NA) | |||||
| Missing | 5 | |||||||||||
| Factor . | Level . | No. of patients . | 12-month MMR rate . | 24-month MMR rate . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentages . | P . | OR (95% CI) . | Percentagesd . | P . | OR (95% CI) . | |||||||
| No MMR . | MMR . | Unifactor analysis . | Multifactor analysis . | No MMR . | MMR . | Unifactor analysis . | Multifactor analysis . | |||||
| Sokal Score at diagnosis | Good | 26 | 40.0 | 60.0 | .063 | .244 | 1.19 (0.19-7.32) | 20.0 | 80.0 | .044 | .788 | 1.94 (0.28-13.30) |
| Intermediate | 30 | 63.3 | 36.7 | 0.40 (0.08-2.10) | 33.3 | 66.7 | 1.46 (0.34-6.19) | |||||
| Poor | 28 | 71.4 | 28.6 | 1 (NA) | 53.6 | 46.4 | 1 (NA) | |||||
| Missing | 19 | |||||||||||
| Hasford Score at diagnosis | Low | 42 | 41.5 | 58.5 | .005 | .278 | 5.08 (0.69-37.6) | 19.5 | 80.5 | .006 | .575 | 2.81 (0.41-19.34) |
| Intermediate | 21 | 66.7 | 33.3 | 2.79 (0.42-18.52) | 42.9 | 57.1 | 1.56 (0.31-7.84) | |||||
| High | 19 | 89.5 | 10.5 | 1 (NA) | 63.2 | 36.8 | 1 (NA) | |||||
| Missing | 21 | |||||||||||
| Age | < 50 | 52 | 54.9 | 45.1 | .842 | .288 | 1.72 (0.63-4.70) | 29.4 | 70.6 | .216 | .074 | 3.02 (0.90-10.16) |
| 50+ | 51 | 56.9 | 43.1 | 1 (NA) | 41.2 | 58.8 | 1 (NA) | |||||
| Sex | Male | 66 | 62.1 | 37.9 | .088 | .374 | 1.58 (0.57-4.35) | 39.4 | 60.6 | .243 | .079 | 3.13 (0.88-11.15) |
| Female | 37 | 44.4 | 55.6 | 1 (NA) | 27.8 | 72.2 | 1 (NA) | |||||
| Spleen size at diagnosis | < 5 | 55 | 42.6 | 57.4 | < .001 | < .001 | 6.48 (2.27-18.47) | 22.2 | 77.8 | .002 | .003 | 5.13 (1.73-15.26) |
| 5+ | 39 | 79.5 | 20.5 | 1 (NA) | 53.9 | 46.1 | 1 (NA) | |||||
| Missing | 9 | |||||||||||
| % Ph+ cells | < 90 | 15 | 28.6 | 71.4 | .029 | .118 | 3.08 (0.75-12.65) | 7.1 | 92.9 | .038 | .241 | 3.83 (0.41-36.16) |
| 90+ | 83 | 61.5 | 38.5 | 1 (NA) | 41.0 | 59.0 | 1 (NA) | |||||
| Missing | 5 | |||||||||||
| Basophils (×10−9/L) (pretreatment) | ≤ 1 | 72 | 46.5 | 53.5 | .005 | .004 | 5.82 (1.74-19.39) | 31.0 | 69.0 | .171 | .473 | 1.53 (0.48-4.87) |
| > 1 | 31 | 77.4 | 22.6 | 1 (NA) | 45.2 | 54.8 | 1 (NA) | |||||
| Eosinophils (×10−9/L) (pretreatment) | < 0.5 | 74 | 56.2 | 43.8 | .927 | .724 | 6.33 (1.72-23.22) | 37.0 | 63.0 | .571 | .816 | 1.15 (0.36-3.72) |
| 0.5+ | 29 | 55.2 | 44.8 | 1 (NA) | 31.0 | 69.0 | 1 (NA) | |||||
| Platelets (×10−9/L) (pretreatment) | < 450 | 68 | 61.2 | 38.8 | .137 | .020 | 0.28 (0.09-0.82) | 38.8 | 61.2 | .306 | .136 | 0.41 (0.12-1.33) |
| 450+ | 35 | 45.7 | 54.3 | 1 (NA) | 28.6 | 71.4 | 1 (NA) | |||||
| White cells (×10−9/L) (pretreatment) | < 20 | 66 | 55.4 | 44.6 | .893 | .565 | 0.72 (0.24-2.19) | 35.4 | 64.6 | .980 | .625 | 1.32 (0.43-4.01) |
| 20+ | 37 | 56.8 | 43.2 | 1 (NA) | 35.1 | 64.9 | 1 (NA) | |||||
| PB blasts (pretreatment) | < 0.2 | 73 | 54.8 | 45.2 | .728 | .366 | 0.49 (0.10-2.29) | 37.0 | 63.0 | .367 | .260 | 0.34 (0.05-2.21) |
| 0.2+ | 16 | 50.0 | 50.0 | 1 (NA) | 25.0 | 75.0 | 1 (NA) | |||||
| Missing | 14 | |||||||||||
| Glivec average daily dose | 600, 600 | 50 | 44.0 | 56.0 | .110 | .130 | 5.40 (1.20-24.37) | 18.0 | 82.0 | .003 | .004 | 10.51 (2.67-41.42) |
| First 6 months, second 6 months | 600, < 600 | 10 | 50.0 | 50.0 | 2.79 (0.39-20.02) | 50.0 | 50.0 | 1.42 (0.26-7.79) | ||||
| < 600, 600 | 20 | 60.0 | 40.0 | 1.89 (0.34-10.41) | 30.0 | 70.0 | 5.59 (1.20-26.03) | |||||
| < 600, < 600 | 18 | 77.8 | 22.2 | 1 (NA) | 66.7 | 33.3 | 1 (NA) | |||||
| Missing | 5 | |||||||||||